Would you offer a 2nd generation anti-AR or abiraterone after progression on ADT in patients with metastatic AR+, HER2 expressing salivary gland carcinoma?

Due to the rarity of the condition, there is limited data that strongly support any intervention in this situation. However, I see 2 potential targets in this case: HER 2 and AR. It would be helpful to know what these patients have been treated with before.

If only AR was targeted, adding a HER2 age...